Experiences with Immunomodulant Agents in HIV Infections

Adriano Lazzarin(Vita-Salute San Raffaele University), M. Moroni(University of Milan), Fabio Franzetti(Luigi Sacco Hospital), Paola Cinque(University of California San Diego), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), María Orietta Borghi(IRCCS Istituto Auxologico Italiano), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Acta Haematologica
February 25, 2009
10.1159/000205909
Cited by 4

Related Papers

Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
|New England Journal of Medicine|2003|653
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
|The Lancet|2009|620
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors
|Clinical Microbiology and Infection|2020|391
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia
|New England Journal of Medicine|2022|309